One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Polycystic Ovarian Syndrome Treatment Market

[ 英語タイトル ] Polycystic Ovarian Syndrome Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0083389
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Abbott Laboratories
- AstraZeneca PLC
- Bayer AG
- Takeda Pharmaceutical Company Limited
- Ferring BV
- Merck KGaA
- Novartis International AG
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Limited

[Report Description]

Polycystic ovary syndrome (PCOS) is a common hormonal endocrine disorder that affects women of childbearing age (15 to 49 years). This disease is characterized by the formation of cysts on the ovaries leading to an insufficiency of the ovulation initiating hormone in the female body. According to the Centers for Disease Control & Prevention (CDC), polycystic ovary syndrome (PCOS) is the most common cause of female infertility. Moreover, the progression of this condition can lead to metabolic abnormalities, which is likely to result in the development of type 2 diabetes, if the syndrome is not treated on time. The severity of the disorder increases the risk of developing uterine and endometrial cancers in patients. Thus, early diagnosis and effective treatment are significant for a successful recovery. The increasing burden of PCOS and no targeted therapy for PCOS being available in the market creates a need to develop therapies to treat them. Thus it becomes one of the primary factors to drive the PCOS treatment market. However, the side effects of symptomatic treatment drugs and lack of approved drugs directly targeting PCOS disease drugs act as among the major restraints to the PCOS treatment market.

Key Market Trends

Laparoscopic Ovarian Drilling is Estimated to Hold Largest Share Over the Forecast Period

Laparoscopic Ovarian Drilling is among the most common surgeries performed by the doctors in critical conditions. Since the fertility problems faced by the women are quite predominant because of this condition, and response to medications weakens over time, the surgery performed via a thin microscope though the abdomen is majorly preferred across the geography. Though this technique is largely adopted, but there are certain risks associated such as lower abdominal pain, bleeding, damage or scarring of the reproductive organs, and infection. Moreover, women with polycystic ovarian syndrome (PCOS) appear to be three times more likely to develop endometrial cancer. The risk of ovarian cancer is also increased in women with PCOS. In addition, the cost-effective procedures drives the patients towards this surgical procedure for easy treatment of the disease. Thus, it is estimated to have a major share, over the forecast period.

North America is Estimated to Have Largest Share in the Global Market

The United States and Canada are highly advanced in terms of new technology procurement, early release of drugs in the market, better reimbursement policies and presence of multiple local and global biopharmaceutical companies. Along with this, there is a steady rise in medical tourism in these countries over the past two decades, which also approach these countries for one of the best medical treatments. The need to ease the treatment and procedures has evolved significantly in past one decade which has given rise to several R&D investments and venture partners funding for pharmaceutical companies to invest into PCOS treatment in North America.

Competitive Landscape

The major market players are focusing on symptomatic treatments and several have their drugs in clinical trials, but not approved for marketing. There is a growing focus on surgeries, for which many medical devices are inclined towards. Some of the major players in the market are Bayer AG, Ferring BV, Merck KGaA, Novartis, Pfizer, and Takeda, Teva Pharmaceutical Industries Limited, among others.

Furthermore, in 2020, Evotec SE and Bayer AG announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration with participation from Celmatix Inc. to develop multiple clinical candidates for the treatment of polycystic ovary syndrome, which is expected to drive the market in the forecats period.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Burden of PCOS
4.2.2 Growth in Initiatives by Government and Private Players to Raise Awareness
4.3 Market Restraints
4.3.1 Adverse Effects Associated with Treatment
4.3.2 Lack of FDA Approved Drugs Specific to Polycystic Ovarian Syndrome (PCOS)
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Treatment
5.1.1 Drug Class Contraceptives Insulin-sensitizing Agent Antidepressants Anti-obesity Others
5.1.2 Surgery Ovarian Wedge Resection Laparoscopic Ovarian Drilling Other Surgeries
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe France Germany United Kingdom Italy Spain Rest of Europe
5.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.2.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 AstraZeneca PLC
6.1.3 Bayer AG
6.1.4 Takeda Pharmaceutical Company Limited
6.1.5 Ferring BV
6.1.6 Merck KGaA
6.1.7 Novartis International AG
6.1.8 Pfizer Inc.
6.1.9 Sanofi SA
6.1.10 Teva Pharmaceutical Industries Limited




Recommended reports